Tesaro, Inc. Summarizes Phase 3 Rolapitant Data Presented At The 2014 American Society of Clinical Oncology Annual Meeting And Provides An Update On Niraparib Development Strategy
Published: Jun 02, 2014
CHICAGO, June 1, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from three Phase 3 trials of rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV), were presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Help employers find you! Check out all the jobs and post your resume.